Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.

European journal of clinical pharmacology - 1 Sept 2003

Lindh Jonatan D, Annas Anita, Meurling Lennart, Dahl Marja-Liisa, AL-Shurbaji Ayman

Abstract excerpt

OBJECTIVE: To study the influence of CYP3A4 inhibition by ketoconazole on the disposition of venlafaxine in individuals with different CYP2D6 pheno- and genotypes. METHODS: In an open two-phase study, 21 healthy volunteers with known CYP2D6 pheno- and genotype [14 extensive metabolisers (EMs), 7 poor metabolisers (PMs)] were given a single oral dose of venlafaxine (50 mg to EMs and 25 mg to PMs). Plasma and urine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antidepressive Agents, Second-Generation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cyclohexanols

Share to Cytochrome P-450 Enzyme Inhibitors

Share to Debrisoquin

Share to Drug Interactions

Share to Half-Life

Share to Venlafaxine Hydrochloride

Source

Identifiers

PMID: 12898080
DOI: 10.1007/s00228-003-0627-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.PMID 12898080Read ↗

Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.Semantic proximity Read ↗

Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.Semantic proximity Read ↗

Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.Semantic proximity Read ↗

Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.Semantic proximity Read ↗

Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.Semantic proximity Read ↗

The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.Semantic proximity Read ↗

Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.Semantic proximity Read ↗

Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.Semantic proximity Read ↗

Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor.Semantic proximity Read ↗

Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.Semantic proximity Read ↗

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.Semantic proximity Read ↗

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.